<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385176</url>
  </required_header>
  <id_info>
    <org_study_id>NECTAR-1109</org_study_id>
    <nct_id>NCT01385176</nct_id>
  </id_info>
  <brief_title>Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)</brief_title>
  <acronym>NECTAR-HF</acronym>
  <official_title>Neural Cardiac Therapy for Heart Failure Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve
      stimulation in heart failure patients with a New York Heart Association Class III, an
      ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than
      130 ms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to assess the impact of right vagal nerve stimulation on
      left ventricular remodeling, functional capacity, quality of life, and other measures in
      heart failure patients over a 6-month period. In addition, the study will assess the safety
      of the NECTAR-HF study system over an 18-month period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2011</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LVend systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular End-systolic Dimension (LVESD)</measure>
    <time_frame>LVESD at Baseline and at 6-months post Baseline</time_frame>
    <description>Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.
The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.
The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Surviving Participants</measure>
    <time_frame>18-months</time_frame>
    <description>As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LVEF, Left Ventricular Ejection Fraction</measure>
    <time_frame>LVEF at Baseline and at 6-months after Baseline</time_frame>
    <description>LVEF, left ventricular ejection fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity, Peak VO2</measure>
    <time_frame>Measurements at Baseline and at 6-months after Baseline</time_frame>
    <description>Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESV, Left Ventricular End Systolic Volume</measure>
    <time_frame>At Baseline and at 6-months after Baseline</time_frame>
    <description>Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.
The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.
Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.
Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.
Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implant of investigational device system</intervention_name>
    <description>Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Titration during the randomization phase</intervention_name>
    <description>Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.</description>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Titration after the randomization phase</intervention_name>
    <description>Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Blood draw before implant and 6 months after implant at the end of the randomization phase.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or above, and of legal age to give informed consent specific to national laws

          -  Willing and capable of providing informed consent

          -  Capable of participating in all testing associated with this clinical investigation

          -  Stable symptomatic heart failure NYHA class II-III

          -  Left ventricular (LV) ejection fraction equal or smaller than 35 %

          -  Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater

          -  Prescribed to optimal pharmacologic therapy

        Exclusion Criteria:

          -  QRS larger than 130 ms

          -  Patients who have been hospitalized for heart failure and who required the use of HF
             IV therapy within 30 days before enrollment

          -  Patients unable to tolerate anesthesia required for implant

          -  Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass
             graft, cerebral vascular accident, or transient ischemic attack within previous 90
             days before enrollment

          -  Patients whose primary cause of heart failure is mitral or aortic valve disease, with
             a severe classification

          -  Patients with persistent or permanent atrial fibrillation within 90 days prior to
             enrollment

          -  Pacemaker indicated patients

          -  Patients whose heart failure is due to congenital heart disease

          -  Patients who have started treatment for sleep apnea or sleep disordered breathing with
             therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen
             supplementation within the previous 6 months prior to enrollment

          -  Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy
             (e.g. amyloidosis, sarcoidosis)

          -  Patients with documented chronic obstructive lung disease

          -  Patients on or indicated for renal dialysis

          -  Type 1 diabetic patients

          -  Type 2 diabetic patients that have been treated with insulin for more than 5 years
             prior to enrollment

          -  Patients with a life expectancy of less than 12 months per physician judgment

          -  Patients involved in any concurrent clinical investigation

          -  Women of childbearing potential who are or might be pregnant at the time of the study
             or breastfeeding

          -  Patients with a prior cardiac transplant or expecting a heart transplant operation
             within the next 12 months

          -  Patients with a prior vagotomy

          -  Patients with prior or existing vagal nerve stimulation treatment

          -  Patients implanted with any active implantable medical device other than a left sided
             single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar
             sensing, or a left sided CRT device with each sensing channel programmed to either
             bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year
             prior to enrollment. The total number of CRT patients will not exceed 30

          -  Patients with locally implanted semi-/permanent devices such as vascular catheters,
             etc. that would interfere with the NECTAR-HF study system

          -  Patients with previously implanted devices on the right side that became infected
             before removal

          -  Patients with previous neck surgery and resultant scar formation that interferes with
             the ability to implant the study system on the right side of the neck
             (Thyroid/parathyroid, carotid artery etc)

          -  Patients with known recurrent nerve paralysis

          -  Patients who have undergone radiotherapy for thyroid disease/cancer

          -  Patients who have existing or prior tracheotomy

          -  Patients with severe vertebral cervical disease and limited mobility in the neck;
             includes those that frequently wear a brace

          -  Patients with carotid murmur/vascular bruit/carotid artery lesion

          -  Patients with known/suspected vascular malformation in carotid/vertebral circulatory
             bed

          -  Patients who are likely to need an MRI of the neck area because of previous medical
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faiez Zannad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Nancy</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Cardiologique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <state>Brandenburg</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. Dei Colli - Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra, Avenida Pio XII s/n</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol, NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital, NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L14 3PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital, University College London Hospitals, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>De Ferrari GM, Tuinenburg AE, Ruble S, Brugada J, Klein H, Butter C, Wright DJ, Schubert B, Solomon S, Meyer S, Stein K, Ramuzat A, Zannad F. Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. Eur J Heart Fail. 2014 Jun;16(6):692-9. doi: 10.1002/ejhf.80. Epub 2014 May 20.</citation>
    <PMID>24846173</PMID>
  </reference>
  <results_reference>
    <citation>Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D'Onofrio A, Solomon SD, Wold N, Ruble SB. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015 Feb 14;36(7):425-33. doi: 10.1093/eurheartj/ehu345. Epub 2014 Aug 31.</citation>
    <PMID>25176942</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <results_first_submitted>February 17, 2017</results_first_submitted>
  <results_first_submitted_qc>December 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2020</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Congestive heart failure</keyword>
  <keyword>New York Heart Association Class II-III</keyword>
  <keyword>Vagal therapy</keyword>
  <keyword>Vagal nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment Start: 21-Sep-2011. First implant: 28-Sep-2011.Last Implant: 20-June-2013.
118 patients enrolled, 96 were found to be eligible and were implanted across 24 centres (7 sites with 5–10 implants, 1 site with 13 implants).
95 patients were randomized.</recruitment_details>
      <pre_assignment_details>22 patients were excluded after enrollment. 18 patients did not meet the inclusion criteria. 4 patients decided to withdraw their consent.
96 patients were finally implanted with the investigational device. One patient died after implant and before randomization. Randomization was done only after the investigational device implant had occurred.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Therapy</title>
          <description>Vagus nerve stimulation system was implanted in the Therapy group as well as in the control group.
Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON, Therapy) or control (VNS OFF, Control) for a 6-month period.
The experimental arm was receiving vagus nerve stimulation soon after implant. Patients randomized to control arm were not receiving right vagal nerve stimulation for the first 6-months post-implant, after which they did also receive therapy.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Control group was implanted with study system like the experimental arm, but did receive no therapy until 6-month cross-over.
Vagal Nerve Stimulation System was implanted but inactive for the first 6 months after implant:
Patients randomized to control arm did not receive right vagal nerve stimulation for the first 6-months post-implant, after which they will also receive therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63">The randomization phase of the study started after implant of the investigational device system.</participants>
                <participants group_id="P2" count="32">The randomization phase of the study started after implant of the investigational device system.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62">The study randomization phase ended after all patients have had their 6 month follow-up visit.</participants>
                <participants group_id="P2" count="30">The study randomization phase ended after all patients have had their 6 month follow-up visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>6-18 Month All VNS Active</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62">Primary Study Phase ended with completion of the 18 months follow-up visit for the last patient</participants>
                <participants group_id="P2" count="30">Primary Study Phase ended with completion of the 18 months follow-up visit for the last patient</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Heart Transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients had a documented LVejection fraction (LVEF) of ≤ 35%, an LV end diastolic dimension (LVEDD) of ≥55 mm, and a New York Heart Association (NYHA) classification of II or III. Patients also had been treated with medical therapy per European heart failure guidelines for at least 30 days prior to enrolment.</population>
      <group_list>
        <group group_id="B1">
          <title>Therapy</title>
          <description>Therapy group was implanted with study system like the control arm, but did receive therapy soon after implant</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Control group was implanted with study system like the experimental arm, but will receive no therapy until 6-month cross-over.
Vagal Nerve Stimulation System was implanted but inactive for the first 6 months: Patients randomized to therapy arm with receive right vagal nerve stimulation. Patients randomized to control arm will not receive right vagal nerve stimulation for the first 6-months post-implant, after which they will also receive therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="12.2"/>
                    <measurement group_id="B2" value="59.3" spread="10.1"/>
                    <measurement group_id="B3" value="59.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="5.9"/>
                    <measurement group_id="B2" value="31.2" spread="5.1"/>
                    <measurement group_id="B3" value="29.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Loop diuretics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular End-systolic Dimension (LVESD)</title>
        <description>Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.
The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.
The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).</description>
        <time_frame>LVESD at Baseline and at 6-months post Baseline</time_frame>
        <population>The sign (- ) indicates a reduction in the LVESD. Participants without paired endpoint data did not contribute to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Vagus nerve stimulation system was implanted. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.
The experimental arm was receiving vagus nerve stimulation starting at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group was implanted with study system like the experimental arm, but did not receive vagus nerve stimulation for the first 6 months after Baseline, after which they will also receive vagus nerve stimulation.
Vagal Nerve Stimulation System was implanted but inactive for the first 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End-systolic Dimension (LVESD)</title>
          <description>Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.
The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.
The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).</description>
          <population>The sign (- ) indicates a reduction in the LVESD. Participants without paired endpoint data did not contribute to the analysis.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.25"/>
                    <measurement group_id="O2" value="-0.08" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Surviving Participants</title>
        <description>As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.</description>
        <time_frame>18-months</time_frame>
        <population>Therapy group received VNS from implant to 18 months. Control group received VNS from 6 months to 18 months. These follow-up periods contributed to the endpoint analysis. Both groups were combined for mortality endpoint analysis. Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients in Active VNS Periods</title>
            <description>All patients in VNS active study periods. Therapy 0-18 months and Control 6-18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Surviving Participants</title>
          <description>As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.</description>
          <population>Therapy group received VNS from implant to 18 months. Control group received VNS from 6 months to 18 months. These follow-up periods contributed to the endpoint analysis. Both groups were combined for mortality endpoint analysis. Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.</population>
          <units>Percentage of participants surving</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVEF, Left Ventricular Ejection Fraction</title>
        <description>LVEF, left ventricular ejection fraction.</description>
        <time_frame>LVEF at Baseline and at 6-months after Baseline</time_frame>
        <population>LVEF echocardiographic measurements were made at Baseline and at 6 months after Baseline. Participants without paired endpoint data did not contribute to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Vagus nerve stimulation system was implanted. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.
The experimental arm was receiving vagus nerve stimulation starting at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group was implanted with study system like the experimental arm, but did not receive vagus nerve stimulation for the first 6 months after Baseline, after which they also did receive vagus nerve stimulation.
Vagal Nerve Stimulation System was implanted but inactive for the first 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LVEF, Left Ventricular Ejection Fraction</title>
          <description>LVEF, left ventricular ejection fraction.</description>
          <population>LVEF echocardiographic measurements were made at Baseline and at 6 months after Baseline. Participants without paired endpoint data did not contribute to the analysis.</population>
          <units>% of blood ejected from ventricle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="6.0"/>
                    <measurement group_id="O2" value="30.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="6.4"/>
                    <measurement group_id="O2" value="32.1" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Capacity, Peak VO2</title>
        <description>Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.</description>
        <time_frame>Measurements at Baseline and at 6-months after Baseline</time_frame>
        <population>Participants without paired endpoint data did not contribute to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Vagus nerve stimulation system was implanted. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.
The experimental arm was receiving vagus nerve stimulation starting at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group was implanted with study system like the experimental arm, but did not receive vagus nerve stimulation for the first 6 months after Baseline, after which they did also receive vagus nerve stimulation.
Vagal Nerve Stimulation System was implanted but inactive for the first 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Capacity, Peak VO2</title>
          <description>Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.</description>
          <population>Participants without paired endpoint data did not contribute to the analysis.</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="3.9"/>
                    <measurement group_id="O2" value="15.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="4.4"/>
                    <measurement group_id="O2" value="14.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LVESV, Left Ventricular End Systolic Volume</title>
        <description>Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm</description>
        <time_frame>At Baseline and at 6-months after Baseline</time_frame>
        <population>Measurements of LVESV, left ventricular end systolic volume at Baseline and at 6-months after Baseline. Participants without paired endpoint data did not contribute to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapy</title>
            <description>Vagus nerve stimulation system was implanted. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.
The experimental arm was receiving vagus nerve stimulation starting at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control group was implanted with study system like the experimental arm, but did not receive vagus nerve stimulation for the first 6 months after Baseline, after which they did also receive vagus nerve stimulation.
Vagal Nerve Stimulation. System was implanted but inactive for the first 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>LVESV, Left Ventricular End Systolic Volume</title>
          <description>Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm</description>
          <population>Measurements of LVESV, left ventricular end systolic volume at Baseline and at 6-months after Baseline. Participants without paired endpoint data did not contribute to the analysis.</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.7" spread="58.5"/>
                    <measurement group_id="O2" value="164.0" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months after Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.5" spread="57.1"/>
                    <measurement group_id="O2" value="152.1" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events information collected during the randomization phase, (6 month) is referred to. During this time period the primary efficicacy endpoint measurements were done and information collected. Only during these initial 6 months there were two goups of patients. After 6 month all patients had received vagus nerve stimulation. An additional Arm/Group (&quot;All Patients - 6 to 18 Months&quot; ) was added to present AEs collected from end of randomization phase until end of safety endpoint period.</time_frame>
      <desc>Adverse Event Definitions as per ISO 14155 were utilized. The study had only patients from European countries enrolled.</desc>
      <group_list>
        <group group_id="E1">
          <title>Therapy</title>
          <description>Vagus nerve stimulation system was implanted in the Therapy group as well as in the control group.
Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON, Therapy) or control (VNS OFF, Control) for a 6-month period.
Patients randomized to therapy arm were receiving right vagal nerve stimulation shortly after implant.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Control group was implanted with study system like the experimental arm, but did receive no therapy until 6-month cross-over.
Patients randomized to control arm did not receive right vagal nerve stimulation for the first 6-months post-implant, after which they did also receive therapy.</description>
        </group>
        <group group_id="E3">
          <title>All Patients - 6 to 18 Months</title>
          <description>All patients were receiving vagus nerve stimulation after the initial 6 months of randomization.
Three of the initially 95 randomized patients died before the end of the randomization phase, reducing the number to 92 patients.
Note, 5 patients did not complete the Randomization phase with the 6 month follow up visit, but were still participating in the study at the time the Randomization Phase Analysis was done. These 5 patients were at risk to have an AE and were included in this analysis set (N=92)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HF hospitalization, anticipated</sub_title>
                <description>anticipated Heart Failure hospitalizations</description>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" events="32" subjects_affected="18" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cardiovascular - Non Heart Failure, anticipated</sub_title>
                <description>anticipated Cardiovascular Serious Adverse events, which were not related to Heart Failure</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" events="26" subjects_affected="16" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Heart Failure Hospitalizations, unanticipated</sub_title>
                <description>unanticipated Heart Failure Hospitalizations</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cardiovascular - Non Heart Failure, unanticipated</sub_title>
                <description>unanticipated Cardiovascular - Non Heart Failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Death, anticipated</sub_title>
                <description>anticpated death due to any cause</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Death, unanticipated</sub_title>
                <description>Death, unanticipated, due to any cause</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non Cardiocascular, anticipated</sub_title>
                <description>Other anticipated Non Cardiocascular serious adverse events</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E3" events="33" subjects_affected="22" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Other Non Cardiocascular, unanticipated</sub_title>
                <description>Other unanticipated Non Cardiocascular</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Investigational device system related, anticipated</sub_title>
                <description>anticipated Investigational device system related serious adverse device effects</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Investigational device system related, unanticipated</sub_title>
                <description>unanticipated Investigational device system related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary, anticipated</sub_title>
                <description>anticipated Genitourinary Serious Adverse Events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Genitourinary, unanticipated</sub_title>
                <description>unanticipated Genitourinary</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Serious Adverse Events, anticipated</sub_title>
                <description>anticipated Pulmonary Serious Adverse Events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pulmonary Serious Adverse Events, unanticipated</sub_title>
                <description>unanticipated Pulmonary Serious Adverse Events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular HF related, anticipated</sub_title>
                <description>anticipated Cardiovascular Heart Failure related non serious adverse events</description>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E3" events="31" subjects_affected="21" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cardiovascular - not HF related, anticipated</sub_title>
                <description>anticipated Cardiovascular - not Heart Failure related adverse events</description>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="63"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E3" events="40" subjects_affected="28" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cardiovascular HF related, unanticipated</sub_title>
                <description>unanticipated Cardiovascular HF related non-serious adverse events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cardiovascular - not HF related, unanticipated</sub_title>
                <description>Cardiovascular - not HF related, unanticipated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other Non-cardiovascular, anticipated</sub_title>
                <description>Other Non-cardiovascular non-serious adverse events, anticipated</description>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E3" events="56" subjects_affected="34" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Other Non-cardiovascular, unanticipated</sub_title>
                <description>Other Non-cardiovascular, unanticipated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigational System-Related anticipated</sub_title>
                <description>Investigational System-Related non-serious adverse events, anticipated</description>
                <counts group_id="E1" events="55" subjects_affected="32" subjects_at_risk="63"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E3" events="34" subjects_affected="25" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Investigational System-Related unanticipated</sub_title>
                <description>Investigational System-Related unanticipated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary, anticipated</sub_title>
                <description>Genitourinary non - serious, anticipated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Genitourinary, unanticipated</sub_title>
                <description>Genitourinary, unanticipated non serious</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary non serious adverse events, anticipated</sub_title>
                <description>anticipated Pulmonary non serious adverse events (non-cardiovascular)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pulmonary non serious adverse events, unanticipated</sub_title>
                <description>Pulmonary non serious adverse events, unanticipated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Inappropriate patient selection may have also contributed to the neutral findings. In the present study, therapy patients experienced side effects (e.g. neck pain, coughing), which limited programming to low stimulation amplitudes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principal Investigator of the Study, Prof. Faiez Zannad</name_or_title>
      <organization>Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy, France</organization>
      <phone>+33 3 83 15 73 22</phone>
      <email>f.zannad@chu-nancy.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

